[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University Hospital, Antwerp\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":687},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,58,0,25,[9,43,68,90,119,142,172,199,230,252,278,298,325,349,367,391,418,445,471,502,526,569,594,619,663],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100650775","a-prospective-observational-study-to-evaluate-the-safety-and-feasibility-of-continuous-renal-replacement-therapy-with-regional-citrate-anticoagulation-in-a-cohort-critical-ill-patients-with-acute-kidney-injury-and-presumed-absent-citrate-metabolism-100650775",false,"NCT07751874","A Prospective, Observational Study to Evaluate the Safety and Feasibility of Continuous Renal Replacement Therapy With Regional Citrate Anticoagulation in a Cohort Critical Ill Patients With Acute Kidney Injury and Presumed Absent Citrate Metabolism","CAT-RISK","Inclusion Criteria:\n\n* Need for renal replacement therapy in the ICU with any of the following criteria:\n* anticipation of severely impaired citrate metabolism (serum lactate ≥ 5 mmol\u002Fl in patients with shock or requirement of a dextrose drip to prevent hypoglycemia or spontaneous INR \\> 3 and\u002For requirement of fresh frozen plasma to maintain INR \\\u003C 3 in patients with cirrhosis or acute liver failure or acute on chronic liver failure)\n* development of citrate toxicity under CRRT with RCA due to worsening citrate metabolism\n\nExclusion Criteria:\n\n* Pregnancy\n* A known hypersensitivity to citrate compounds\n* Refusal of informed consent","ALL","18 Years",{"count":20,"type":21},50,"ESTIMATED","OBSERVATIONAL","Use of regional citrate anticoagulation in an at risk population with decreased citrate metabolism. This study assesses the feasibility and safety of regional citrate anticoagulation in this population.",[25],"Acute Kidney Injury",[27,28,29],"Acute kidney injury","Regional citrate anticoagulation","citrate metabolism","NOT_YET_RECRUITING","2026-08-03",{"date":33,"type":34},"2026-08-07","ACTUAL",{"date":36,"type":21},"2026-10-15",{"date":38,"type":21},"2028-07-01",{"name":40,"class":41},"University Hospital, Antwerp","OTHER",1,{"id":44,"slug":45,"hasResults":12,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":42},"100645656","the-effect-of-anatomy-based-fitting-on-the-perception-of-speech-in-noise-and-music-in-single-sided-deaf-cochlear-implant-users-100645656","NCT07703800","The Effect of Anatomy-based Fitting on the Perception of Speech in Noise and Music in Single-sided Deaf Cochlear Implant Users","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Post-lingual onset of unilateral severe-to-profound sensorineural hearing loss\n* Contralateral hearing \\\u003C 30 dB HL (PTA measured at 500Hz, 1kHz, 2kHz en 4 kHz)\n* Post-operative Computed Tomography (CT) scan of the CI elec-trode available\n* Subject implanted with MED-EL cochlear implant(s)\n* Subjects received a Flex20, Flex24, Flex28, FlexSoft, Flex34 or Standard electrode\n* Subject planned to receive a SONNET 2, SONNET 3 or RONDO 3 audio processor on the newly implanted side\n* Newly implanted CI users\n* The most apical active electrode contact has to be inserted at least 540°\n* Minimum of 10 active channels can be activated\n* Fluent in the language of the test centre\n* Signed and dated Informed Consent Form (ICF) before the start of any study-specific procedure\n\nExclusion Criteria:\n\n* Lack of compliance with any inclusion criteria\n* Implanted with C40+, C40X and C40C\n* Implanted with an ABI or Split electrode array\n* Anything that, in the opinion of the Investigator, would place the subject at increased risk or preclude the subject's full compliance with or completion of the study",{"count":50,"type":21},20,"INTERVENTIONAL",[53],"NA","The present study evaluates the effect of anatomy-based fitting on speech perception in noise and music perception in newly implanted single-sided deaf (SSD) CI recipients. Speech perception in noise will be assessed using different spatial configurations of speech and noise. Music perception will be evaluated using objective measurements for melody, harmony, timbre and pitch and using a subjective questionnaire, the Music and Cochlear implant questionnaire (MCIQ). Furthermore, localization and self-reported hearing benefit (HISQUI19, SSQ12) will be assessed.",[56,57,58],"Cochlear Implant","Sensorineural Hearing Loss","Single Sided Deafness","RECRUITING","2026-07-17",{"date":62,"type":34},"2026-07-21",{"date":64,"type":34},"2025-06-26",{"date":66,"type":21},"2027-12",{"name":40,"class":41},{"id":69,"slug":70,"hasResults":12,"nctId":71,"briefTitle":72,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":75,"targetDuration":77,"studyType":22,"phases":4,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":42},"100625819","prospective-evaluation-of-new-metrics-to-assess-cardiovascular-remodeling-in-obstructive-sleep-apnea-100625819","NCT07427589","Prospective Evaluation of New Metrics to Assess Cardiovascular Remodeling in Obstructive Sleep Apnea","CARDOSA","Inclusion Criteria:\n\n* AHI ≥ 15 events\u002Fhour, based on a recent (\\\u003C2 years) PSG, conducted in Antwerp University Hospital\n* Patients must be 18 years or older\n* Patients must be dutch-speaking\n* Patients must be eligible for their therapy (CPAP, MAD or HNS)\n* Willing to participate after informed consent\n\nExclusion Criteria:\n\n* Central apneas accounting for ≥25% of total apneas during baseline polysomnography\n* Patients who have received effective CPAP therapy (defined as CPAP use for ≥4 h\u002Fnight) within the previous 6 months\n* Patients with prior MAD therapy\n* Uncontrolled hypertension\n* Known cardiomyopathy\n* Significant coronary arterial disease\n* Clinically significant valvular heart disease, defined as more than mild left-sided valvular disease or more than moderate right-sided valvular disease\n* Congenital heart disease\n* Participants may be excluded if, after rescoring, outcome measures do not meet predefined criteria",{"count":76,"type":21},270,"1 Year","The goal of this prospective study is to gain insight into the endophenotypic variation in OSA, with a focus on the underlying pathophysiological traits and the cardiovascular alterations associated with the condition. To capture the variability in OSA endophenotypes, novel metrics that extend beyond the AHI will be considered, with particular attention to the sleep-apnea-specific hypoxic burden, the sleep-apnea-specific heart rate response, and pulse wave amplitude drops (PWADs). Since the impact of treatment on cardiovascular parameters remains an important point of interest, the effects of different treatment modalities on cardiovascular changes will be investigated, including continuous positive airway pressure (CPAP), mandibular advancement devices (MADs), and hypoglossal nerve stimulation.",[80,81],"Obstructive Sleep Apnea","Cardiovascular (CV) Risk","2026-06-24",{"date":84,"type":34},"2026-06-29",{"date":86,"type":34},"2026-06-10",{"date":88,"type":21},"2029-12",{"name":40,"class":41},{"id":91,"slug":92,"hasResults":12,"nctId":93,"briefTitle":94,"officialTitle":94,"acronym":95,"eligibilityCriteria":96,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":51,"phases":99,"briefSummary":102,"conditions":103,"keywords":105,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":118},"100498040","phase-1-integration-of-the-pd-l1-inhibitor-atezolizumab-and-wt1dc-vaccination-into-platinumpemetrexed-based-first-line-treatment-for-epithelioid-malignant-pleural-mesothelioma-100498040","NCT05765084","Integration of the PD-L1 Inhibitor Atezolizumab and WT1\u002FDC Vaccination Into Platinum\u002FPemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma","Immuno-MESODEC","Inclusion Criteria:\n\nSubjects must meet all the following criteria to be eligible to participate in the study:\n\n* Signed informed consent\n* Diagnosis with histologically proven epithelioid unresectable MPM (stage I-IV)\n* Age ≥ 18 years at the time of signing informed consent\n* World Health Organization (WHO) performance status 0-1\n* Adequate hematologic and end-organ function, defined by the following laboratory test results, obtained at the time of screening:\n\n  * Absolute neutrophil count (ANC) ≥ 1.5 x 10\\^9\u002FL (1500\u002FμL) without granulocyte colony- stimulating factor support\n  * Lymphocyte count ≥ 0.5 x 10\\^9\u002FL (500\u002FμL)\n  * Platelet count ≥ 100 x 10\\^9\u002FL (100,000\u002FμL) without transfusion\n  * Hemoglobin ≥ 90 g\u002FL (9 g\u002FdL) Patients may be transfused to meet this criterion\n  * Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) ≤ 2.5 x upper limit of normal (ULN), with the following exceptions:\n  * Patients with documented liver metastases: AST and ALT ≤ 5 x ULN\n  * Patients with documented liver or bone metastases: ALP ≤ 5 x ULN\n  * Total bilirubin ≤ 1.5 x ULN with the following exception:\n  * Patients with known Gilbert disease: total bilirubin ≤ 3 x ULN\n  * Creatinine ≤ 1.5 x ULN\n  * Albumin ≥ 25 g\u002FL (2.5 g\u002FdL)\n  * For patients not receiving therapeutic anticoagulation: prothrombin international normalized ration (PT-INR) and activated partial thromboplastin time (APTT) ≤ 1.5 x ULN\n* Negative Human Immunodeficiency Virus (HIV) test at screening\n* Negative hepatitis B surface antigen (HBsAg) test at screening\n* Negative total hepatitis B core antibody (HBcAb) test at screening, or positive total HBcAb test followed by a negative hepatitis B virus (HBV) DNA test at screening\n\n  * The HBV DNA test will be performed only for patients who have a negative HBsAg test and a positive total HBcAb test.\n* Negative hepatitis C virus (HCV) antibody test at screening, or positive HCV antibody test followed by a negative HCV RNA test at screening. The HCV RNA test must be performed for patients who have a positive HCV antibody test.\n* Willing and able to comply with the study protocol, as judged by the treating physician\n* Women of childbearing potential must have a negative serum or urine pregnancy test at the time of screening and agree to use effective contraception (\\\u003C1% failure rate per year) before, during and for at least five months after the last atezolizumab administration or at least hundred days after the last WT1\u002FDC vaccine administration (whichever takes longer). Men must agree to use effective contraception before, during and for at least hundred days after the last study treatment administration.\n\nExclusion Criteria:\n\nSubjects who fulfill any of the following criteria will not be eligible for admission into the study:\n\n* History of malignancy within 3 years prior to initiation of study treatment, with the exception of the cancer under investigation in this study and malignancies with a negligible risk of metastasis or death (e.g., 5-year OS rate \\> 90%), such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer\n* Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases. Asymptomatic patients with treated CNS lesions are eligible, provided that all of the following criteria are met:\n\n  * Measurable disease, per RECIST v1.1, must be present outside the CNS.\n  * The patient has no history of intracranial hemorrhage or spinal cord hemorrhage.\n  * The patient has not undergone stereotactic radiotherapy within 7 days prior to initiation of study treatment, whole-brain radiotherapy within 14 days prior to initiation of study treatment, or neurosurgical resection within 28 days prior to initiation of study treatment.\n  * The patient has no ongoing requirement for corticosteroids as therapy for CNS disease.\n  * If the patient is receiving anti-convulsant therapy, the dose is considered stable.\n  * Metastases are limited to the cerebellum or the supratentorial region (i.e., no metastases to the midbrain, pons, medulla, or spinal cord).\n  * There is no evidence of interim progression between completion of CNS directed therapy and initiation of study treatment.\n  * Asymptomatic patients with CNS metastases newly detected at screening are eligible for the study after receiving radiotherapy and\u002For surgery, with no need to repeat the screening brain scan.\n* History of leptomeningeal disease\n* Active or history of autoimmune disease or immune deficiency, including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, anti-phospholipid antibody syndrome, Wegener granulomatosis, Sjögren syndrome, Guillain-Barré syndrome, or multiple sclerosis, with the following exceptions:\n\n  * Patients with a history of autoimmune-related hypothyroidism who are on thyroid replacement hormone are eligible for the study.\n  * Patients with controlled Type 1 diabetes mellitus who are on an insulin regimen are eligible for the study.\n  * Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis are excluded) are eligible for the study provided all of following conditions are met:\n\n    * Rash must cover \\\u003C 10% of body surface area\n    * Disease is well controlled at baseline and requires only low-potency topical corticosteroids\n    * No occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high potency or oral corticosteroids within the previous 12 months.\n* History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted.\n* Significant cardiovascular disease (such as New York Heart Association Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina\n* Major surgical procedure, other than for diagnosis, within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the study\n* Severe infection within 4 weeks prior to initiation of study treatment, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia, or any active infection that could impact patient safety\n* Prior treatment for MPM\n* Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatment. Patients receiving prophylactic antibiotics (e.g., to prevent a urinary tract infection or chronic obstructive pulmonary disease (COPD) exacerbation) are eligible for the study.\n* Prior allogeneic stem cell or solid organ transplantation\n* Use of any investigational agent within 28 days before study enrollment\n* Pregnant or breastfeeding. Female subjects who are breastfeeding should discontinue nursing prior to the first dose of study treatment and until at least hundred days after the last study treatment administration.\n* Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during atezolizumab treatment or within 5 months after the final dose of atezolizumab.\n* Current treatment with anti-viral therapy for HBV\n* Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies\n* Treatment with systemic immunosuppressive medication (including, but not limited to, corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor-α \\[TNF-α\\] agents) within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during study treatment, with the following exceptions:\n\n  * Patients who received acute, low-dose systemic immunosuppressant medication or a one-time pulse dose of systemic immunosuppressant medication (e.g., 48 hours of corticosteroids for a contrast allergy) may be eligible for the study after Medical Monitor confirmation has been obtained.\n  * Patients who received mineralocorticoids (e.g., fludrocortisone), inhaled or low dose corticosteroids for COPD or asthma, or low-dose corticosteroids for orthostatic hypotension or adrenal insufficiency are eligible for the study.\n* Treatment with systemic immunostimulatory agents (including but not limited to interferons or interleukin-2) within 4 weeks or 5 drug-elimination half-lives of the drug, whichever is longer, prior to initiation of study treatment\n* History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins\n* Known hypersensitivity to Chinese hamster ovary cell products or to any component of the atezolizumab formulation\n* Any other condition, either physical or psychological, or reasonable suspicion thereof on clinical or special investigation, which contraindicates the use of atezolizumab, pemetrexed, cisplatin\u002Fcarboplatin and\u002For WT1\u002FDC vaccination, or may negatively affect patient compliance, or may place the patient at higher risk of potential treatment complications.",{"count":98,"type":21},15,[100,101],"PHASE1","PHASE2","In this multicenter phase I\u002FII trial, the programmed death-ligand 1 (PD-L1) inhibitor atezolizumab and dendritic cells (DCs) loaded with the mesothelioma-associated tumor antigen WT1 will be integrated into platinum\u002Fpemetrexed-based first-line chemotherapy for the treatment of epitheloid malignant pleural mesothelioma (MPM). The general objective is to provide the first-in-human experimental demonstration that the combination of platinum\u002Fpemetrexed-based chemotherapy with atezolizumab and WT1\u002FDC vaccination is feasible and safe, has clinical activity and enables the induction of mesothelioma-specific immune responses in patients with MPM.",[104],"Malignant Pleural Mesothelioma",[106,107,108,109],"Dendritic cell vaccination","Chemo-immunotherapy","Wilms' Tumor 1 (WT1)","Checkpoint inhibition","2026-06-04",{"date":112,"type":34},"2026-06-05",{"date":114,"type":34},"2023-02-24",{"date":116,"type":21},"2027-10",{"name":40,"class":41},3,{"id":120,"slug":121,"hasResults":12,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":126,"targetDuration":4,"studyType":51,"phases":127,"briefSummary":128,"conditions":129,"keywords":132,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":42},"100643764","eccentric-muscle-training-in-cardiac-rehabilitation-100643764","NCT07636343","Eccentric Muscle Training in Cardiac Rehabilitation","Eccentric Muscle Training in Cardiac Rehabilitation: Randomized Controlled Trial to Evaluate Effectiveness and Feasibility in Heart Failure Patients With Reduced Ejection Fraction","Inclusion Criteria:\n\n* HFrEF patients with ejection fraction \\\u003C40%\n* Exercise intolerance (\\\u003C85% of predicted VO2 peak)\n* clinically stable for \\> 6 weeks, optimal medical treatment for \\> 6 weeks\n\nExclusion Criteria:\n\n* Contra indications for cardiac exercise rehabilitation as per consensus guidelines and recommendations\n* Musculoskeletal disorders that hamper (progression in) strength training\n* Non-stabilized acute coronary syndrome\n* Current acute heart failure (decompensation)\n* Patient having sustained a recent (\\\u003C3 months) procedure that could act as a confounder to increase VO2peak (i.e., coronary artery bypass graft surgery, percutaneous coronary intervention, cardiac resynchronization therapy, valve surgery or reparation)",{"count":118,"type":21},[53],"The goal of this interventional study is to assess the training effects in a training schedule in which eccentric overload training and eccentric cycle training are used.\n\nResearchers will compare a training program of eccentric overload training and eccentric cycling training with a traditional training program of strength and cardio training in people with heart failure with reduced ejection fraction.\n\nThis study will be delivered in a cardiac rehabilitation setting.",[130,131],"Strength Training Effects","HFrEF - Heart Failure With Reduced Ejection Fraction",[133],"eccentric muscle training","2026-06-03",{"date":136,"type":34},"2026-06-09",{"date":138,"type":34},"2023-01-20",{"date":140,"type":21},"2027-01-01",{"name":40,"class":41},{"id":143,"slug":144,"hasResults":12,"nctId":145,"briefTitle":146,"officialTitle":146,"acronym":147,"eligibilityCriteria":148,"healthyVolunteers":149,"sex":17,"minAge":150,"maxAge":4,"enrollmentInfo":151,"targetDuration":4,"studyType":51,"phases":153,"briefSummary":154,"conditions":155,"keywords":161,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":42},"100643279","methylated-biomarkers-of-smoking-as-a-selection-tool-in-participants-for-lung-cancer-screening-100643279","NCT07631624","Methylated Biomarkers of Smoking as a Selection Tool in Participants for Lung Cancer Screening","MET-SELS","Cohort 1: Volunteers\n\nInclusion Criteria:\n\n* Age: Must be \\> 50 years of age\n* Smoking History: Includes individuals with and without a smoking history\n\nCohort 2: ZORALCS-study participants\n\nInclusion Criteria:\n\n* Age: 55-74 years old\n* Smoking History: Includes individuals with a smoking history",true,"50 Years",{"count":152,"type":21},1000,[53],"The MET-SELS study aims to revolutionize how we identify individuals for lung cancer screening by moving beyond the limitations of self-reported smoking history. Currently, eligibility for low-dose CT (LDCT) scans relies on \"pack-years\"-a metric often compromised by recall bias, under-reporting, and an inability to account for the biological nuances of smoke inhalation or environmental exposure. Consequently, current criteria miss nearly half of incidental lung cancers.\n\nTo bridge this gap, the study investigates DNA methylation as a stable, objective \"biological footprint\" of smoking. Unlike short-term biomarkers like nicotine or CO levels, specific epigenetic changes in genes such as AHRR and F2RL3 persist long after cessation and correlate accurately with cumulative tobacco exposure.\n\nLed by Professor Dr. Annemiek Snoeckx and a multidisciplinary team at UZA and the Centre for Medical Genetics, the research will analyze saliva samples from two groups: roughly 900 participants from the ZORALCS screening trial and 150 volunteers. By comparing saliva-derived genomic signatures against both self-reported data and professional interviews, the team aims to validate a panel of methylation markers that can pinpoint high-risk individuals with far greater precision.\n\nThe ultimate vision for MET-SELS is to implement a population-based \"saliva-first\" triage system, similar to the FIT test used for colorectal cancer. In this model, high-risk candidates would provide a saliva sample at home; only those with a confirmed epigenetic risk profile would be invited for a LDCT scan, significantly increasing the yield of early-stage lung cancer detection while streamlining healthcare resources.",[156,157,158,159,160],"Epigenetics","DNA Methylation","Lung Cancer Screening","Risk Stratification With Biomarker","Saliva",[162,158,163,164,160],"DNA-methylation","Risk stratification","Smoking",{"date":166,"type":34},"2026-06-08",{"date":168,"type":34},"2025-10-04",{"date":170,"type":21},"2028-01-01",{"name":40,"class":41},{"id":173,"slug":174,"hasResults":12,"nctId":175,"briefTitle":176,"officialTitle":177,"acronym":178,"eligibilityCriteria":179,"healthyVolunteers":149,"sex":17,"minAge":180,"maxAge":4,"enrollmentInfo":181,"targetDuration":4,"studyType":51,"phases":183,"briefSummary":184,"conditions":185,"keywords":187,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":42},"100547585","diagnosing-drug-allergy-the-t-is-the-key-100547585","NCT06409884","Diagnosing Drug Allergy: the T is the Key","Diagnosing Drug Allergy the T is the Key","TAT","Inclusion Criteria:\n\nParticipants are eligible if they:\n\n* Are ≥ 6 years\n* Are capable of informed consent, or if appropriate, participants have an acceptable individual capable of giving consent on the participant's behalf (e.g. parent or guardian of a child under 18 years of age)\n* Have a suspected history of amoxicillin allergy\n\nExclusion Criteria:\n\n* Patients who are lacking capacity or do not have an acceptable individual capable to provide informed consent\n* Pregnant women\n* Breastfeeding women","6 Years",{"count":182,"type":21},300,[53],"The goal of this clinical trial is to validate a newly developed test in the diagnosis of patients with amoxicillin allergy (i.e. T-cell activation test). The main questions the study aims to assess are the reliability and applicability of this test. Participants will be asked to visit the hospital 1, 3 or 5 times during which blood is collected and when applicable, allergy skin testing is performed.",[186],"Amoxicillin Allergy",[188,186,189,190],"Amoxicillin","Allergy","T-cells","2026-05-11",{"date":193,"type":34},"2026-05-14",{"date":195,"type":34},"2024-05-21",{"date":197,"type":21},"2027-09-30",{"name":40,"class":41},{"id":200,"slug":201,"hasResults":12,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":205,"eligibilityCriteria":206,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":207,"enrollmentInfo":208,"targetDuration":4,"studyType":51,"phases":210,"briefSummary":211,"conditions":212,"keywords":214,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":229},"100594535","phase-2-a-phase-iia-study-of-vitamin-d3-tolerogenic-dendritic-cells-toldc-for-multiple-sclerosis-100594535","NCT07020715","A Phase IIa Study of Vitamin D3 Tolerogenic Dendritic Cells (tolDC) for Multiple Sclerosis","An Autologous and Antigen-specific Cell-based Therapy of Vitamin D3-treated and Myelin-derived Peptide Loaded Tolerogenic Dendritic Cells in Subjects With Progressive Forms of Multiple Sclerosis: a Phase IIa, Open-label, Self-controlled, Multi-center Clinical Trial","MS-tolDC_2a","Inclusion Criteria:\n\n* Patient is ≥ 18 years old, and ≤65 years of age, at time of screening visit\n* Diagnosis of MS according to the 2017 McDonald Criteria or more recent criteria\n* Progressive MS by 2014 Lublin MS phenotypic criteria\n* EDSS 2,0 - ≤7,5\n* No clinical evidence of relapses in the past 2 years\n* Ability to understand and the willingness to sign a written informed consent document. Patients must have signed informed consent to participate in the trial.\n* Appropriate venous access\n* Use of adequate contraceptive measures or not of childbearing potential\n\nExclusion Criteria:\n\n* Previous treatment with alemtuzumab, autologous hematopoietic stem cell transplantation or cladribine in the past 3 years.\n* Prior treatment with any investigational agent within 3 months, or 5 half-lives, whichever is longer.\n* Current and ongoing treatment with an approved DMT for MS\n* Treatment with S1P receptor modulators, natalizumab, dimethylfumarate, teriflunomide within the last 3 months prior to study enrolment; last treatment with B cell depleting monoclonal antibodies at least 6 months prior to enrollment and normal CD19 B cell counts at time of enrollment\n* Pregnancy or planning pregnancy in the next 12 months and breast feeding\n* Drug or alcohol abuse\n* Inability to undergo MRI assessments\n* History of or actual signs of immunodeficiency or malignancies (with the exception of treated basal cell carcinoma)\n* Concurrent clinically relevant cardiac, immunological, pulmonary, neurological, renal or other major disease that could impact safety or outcome measures.\n* Active or chronic infection with hepatitis B, C, HIV, syphilis or tuberculosis\n* Splenectomy\n* Dementia or severe psychiatric, cognitive or behavioral problems or other comorbidity that could interfere with the compliance to the protocol.","65 Years",{"count":209,"type":21},14,[101],"The investigators propose to design and conduct a phase IIa clinical trial to treat patients with progressive forms of multiple sclerosis (MS) by vaccination with tolerogenic dendritic cells (tolDC), generated using Good Manufacturing Practices (GMP). Hereby, the investigators want to demonstrate the efficacy and safety of administrating clinical-grade vitamin D3-treated tolDC loaded with myelin-derived peptides to patients with progressive forms of MS. In vitro generation of dedicated and stable immunomodulatory DC followed by in vitro loading of antigens to ensure tolerance and safety of DC-directed therapy is a promising strategy with the potential to induce long term tolerance.",[213],"Multiple Sclerosis",[215,216,217,213,218,219,220],"Tolerogenic dendritic cells","tolDC","Phase IIa","MS","Patient Safety","Efficacy","2026-05-04",{"date":223,"type":34},"2026-05-05",{"date":225,"type":21},"2026-07-01",{"date":227,"type":21},"2029-10-30",{"name":40,"class":41},2,{"id":231,"slug":232,"hasResults":12,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":236,"eligibilityCriteria":237,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":238,"enrollmentInfo":239,"targetDuration":4,"studyType":51,"phases":241,"briefSummary":242,"conditions":243,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":245,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":42},"100545886","referral-of-patients-to-hepatology-with-hepatoscope-100545886","NCT06387745","Referral of Patients to Hepatology With Hepatoscope","Use of Ultrasound Tools to Refer Patients at Risk of Chronic Liver Disease to the Hepatology Consultation (US-REFERRAL)","US-REFERRAL","Inclusion Criteria:\n\n* Patients with any of the following\n\n  * Elevated liver enzymes (AST, ALT, Gamma-GT, AP)\n  * Type 2 diabetes\n  * Elements of metabolic syndrome\n* Patients who consent in written to participate in the Clinical Investigation after being orally informed on the objectives and methods of the Clinical Investigation\n\nExclusion Criteria:\n\n* Patients with active implants such as pacemakers, defibrillators, pumps, etc.\n* Patients presenting wounds at the location where the Hepatoscope probe shall be placed on patients' skin,\n* Pregnant and breastfeeding women,\n* People deprived of their freedom rights.","80 Years",{"count":240,"type":21},200,[53],"Patients identified as being at risk of liver fibrosis because of a positive Fibrosis-4 (FIB-4) test in the primary care setting will be offered be enrolled in the trial and to undergo an Hepatoscope exam (external non-invasive ultrasound imaging exam) to screen for liver fibrosis (with stiffness measurements) and\u002For steatosis (with ultrasound parameters related to fatty liver). All patients presenting with a liver stiffness value of at least 6.5 kilopascal (kPa) will be referred to the tertiary hepatology consultations for further assessment. Hepatoscope measurements will be compared to the standard of care for these patients, as defined at the tertiary hepatology center.",[244],"Chronic Liver Disease",{"date":246,"type":34},"2026-05-08",{"date":248,"type":34},"2025-08-22",{"date":250,"type":21},"2026-12",{"name":40,"class":41},{"id":253,"slug":254,"hasResults":12,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":258,"eligibilityCriteria":259,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":260,"targetDuration":4,"studyType":51,"phases":262,"briefSummary":263,"conditions":264,"keywords":266,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":272,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":277,"locationsCount":229},"100536344","structured-testing-and-treatment-for-obstructive-sleep-apnea-in-patients-with-atrial-fibrillation-100536344","NCT06263608","Structured Testing and Treatment for Obstructive Sleep Apnea in Patients With Atrial Fibrillation","STAROSA Trial - Structured Testing and Treatment for Obstructive Sleep Apnea in Patients With Atrial Fibrillation","STAROSA","Inclusion Criteria:\n\n* Patients in whom AF (paroxysmal or persistent) is diagnosed with a 12-lead ECG\n* Patients who experience symptoms of their AF (mEHRA ≥ 2a)\n* Older than 18 years\n* Owning a smartphone compatible with Fitbit and FibriCheck applications (i.e. recent versions of Apple iOS or Android drivers)\n* Ability to sign the informed consent\n\nExclusion Criteria:\n\n* Patients diagnosed with permanent AF or only atrial flutter\n* Prior\u002Frecent polysomnography evaluation\n* Prior\u002Factive CPAP\u002FBiPAP\u002FASV treatment\n* Cognitive impairment\n* Inability to speak or fully understand Dutch\n* Pacemaker-dependent heart rhythm",{"count":261,"type":21},209,[53],"The main goal of this prospective pre-post implementation study is to investigate how a structured testing and treatment program for obstructive sleep apnea using the NOX T3s device and a Fitbit smartwatch with the FibriCheck algorithm impacts the proportion of atrial fibrillation (AF) in an AF population.\n\nParticipants will wear the NOX T3s respiratory polygraphy device for one night at home. In case of a positive obstructive sleep apnea diagnosis, patients will be referred to the sleep clinic for a polysomnography examination. Patients positively diagnosed with polygraph will be monitored semi-continuously with the Fitbit smartwatch for three months. After the polysomnography examination, the positively diagnosed patients will be monitored semi-continuously for another three months after initiation of treatment (mostly continuous positive airway pressure (CPAP) treatment). Additionally, patients will be administered satisfaction, symptom burden and alcohol consumption questionnaires twice: right after the polysomnography examination and after the 3-month treatment.",[265,80],"Atrial Fibrillation",[267,268,269,270,271],"Atrial fibrillation","Obstructive sleep apnea","Cardiorespiratory polygraphy","Continuous positive airway pressure","Mobile health technology",{"date":246,"type":34},{"date":274,"type":34},"2024-02-23",{"date":276,"type":21},"2028-02",{"name":40,"class":41},{"id":279,"slug":280,"hasResults":12,"nctId":281,"briefTitle":282,"officialTitle":283,"acronym":284,"eligibilityCriteria":285,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":286,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":287,"conditions":288,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":292,"startDateStruct":293,"completionDateStruct":295,"leadSponsor":297,"locationsCount":42},"100512333","long-term-evaluation-of-a-mobile-application-for-follow-up-of-cardiac-patients-cardio2u-study-100512333","NCT05951088","Long-term Evaluation of a Mobile Application for Follow-up of Cardiac Patients (Cardio2U Study)","Long-term Evaluation of a Mobile Application for Follow-up of Cardiac Patients","Cardio2U","Inclusion Criteria:\n\n1. Age ≥ 18 years,\n2. Patients in whom AF or atrial flutter is diagnosed with an electrocardiogram (12-lead, Holter monitor,…) and\u002For patients in whom HF is diagnosed in their medical records,\n3. Patients who are capable of signing the informed consent.\n\nExclusion Criteria:\n\n1. Not able to speak and read Dutch,\n2. Cognitive impaired (e.g. severe dementia),\n3. No smartphone or tablet available.",{"count":240,"type":21},"This trial has to aim to evaluate an innovative, in-house developed mobile application supporting patients in their home environment by actively involving them in different aspects of their condition and treatment. The usability, long-term adherence and patient satisfaction will be studied in patients with atrial fibrillation (AF) and\u002For heart failure (HF).",[289,290,291],"Follow-up","Education","Mobile Health",{"date":246,"type":34},{"date":294,"type":34},"2023-05-23",{"date":296,"type":21},"2026-05-30",{"name":40,"class":41},{"id":299,"slug":300,"hasResults":12,"nctId":301,"briefTitle":302,"officialTitle":303,"acronym":304,"eligibilityCriteria":305,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":306,"targetDuration":4,"studyType":51,"phases":308,"briefSummary":309,"conditions":310,"keywords":313,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":318,"startDateStruct":320,"completionDateStruct":322,"leadSponsor":324,"locationsCount":229},"100609186","monitoring-and-guidance-of-physical-activity-during-the-maintenance-phase-of-cardiac-rehabilitation-the-antwerp-activity-index-100609186","NCT07211282","Monitoring and Guidance of Physical Activity During the Maintenance Phase of Cardiac Rehabilitation: the Antwerp Activity Index","Transmural Physical Activity Monitoring and Guidance During Phase 3 Cardiac Rehabilitation: the Antwerp Activity Index","AMAAI","Inclusion Criteria:\n\n1. Age ≥ 18 years,\n2. Patients in the last phase of phase 2 CR,\n3. Having a smartphone available,\n4. Being capable of signing the informed consent.\n\nExclusion Criteria:\n\n1. Patients with high-risk criteria for safe exercise participation following a cardiac event, including:\n\n   1. Ejection fraction less than 30%\n   2. Decrease in systolic blood pressure of more than 15 mmHg with exercise\n   3. Serious arrhythmias at rest or exercise-induced\n   4. Exercise-induced ischemia indicated by angina more than 2 mm ST segment depression on the ECG\n2. Patients with severe heart failure (NYHA III-IV),\n3. Patients with implantable devices (e.g. pacemakers),\n4. Patients diagnosed with permanent AF,\n5. Patients who do not speak and read Dutch or English,\n6. Patients who have cognitive impairment (e.g. severe dementia).",{"count":307,"type":21},318,[53],"The goal of this clinical trial is to determine whether the AAI activity score can help cardiac rehabilitation patients adhere to physical activity guidelines after participating in an in-hospital cardiac rehabilitation program. The main questions it aims to answer are:\n\n1. Does the AAI activity score have an impact on adherence to physical activity maintenance during phase 3 CR?\n2. Does the AAI activity score predict changes in cardiorespiratory fitness? Researchers will compare participants who use the AAI activity score with those who do not to determine if there are differences in physical activity adherence.\n\nParticipants will:\n\n* Wear a smartwatch to continuously measure heart rate for 4 months;\n* Perform an exercise stress test at the end of the study;\n* Fill in several questionnaires at the end of the study.",[311,312],"Cardiac Rehabilitation","Cardiovascular Disease Prevention",[314,315,316],"physical activity","cardiac rehabilitation","heart rate monitor","2026-04-30",{"date":319,"type":34},"2026-05-06",{"date":321,"type":34},"2025-02-17",{"date":323,"type":21},"2029-01",{"name":40,"class":41},{"id":326,"slug":327,"hasResults":12,"nctId":328,"briefTitle":329,"officialTitle":330,"acronym":331,"eligibilityCriteria":332,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":333,"targetDuration":4,"studyType":51,"phases":335,"briefSummary":336,"conditions":337,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":342,"startDateStruct":344,"completionDateStruct":346,"leadSponsor":348,"locationsCount":42},"100605143","surgical-corncerns-and-psychological-evaluation-of-patients-undergoing-elective-surgery-100605143","NCT07158684","Surgical COrncerns and Psychological Evaluation of Patients Undergoing Elective Surgery","Psychological Evaluation of Patients Undergoing Elective Surgery With Anxiety and Surgical Concerns: a Qualitative Interview Study","SCOPE","Inclusion Criteria:\n\n* ≥ 18 years old\n* Dutch speaking\n* With a planned elective surgery, at the Antwerp University Hospital\n* Score of ≥ 11 on APAIS anxiety subscale\n* Must be able to complete questions on a tablet (digital literacy)\n* Signed informed consen (prescreening informed consent and study participation informed consent)\n\nExclusion Criteria:\n\n* Diagnostic procedures requiring anaesthesia",{"count":334,"type":21},30,[53],"This study wants to obtain more information regarding the patient's concerns since concerns of the patient about the procedure is found as a predictor for the development of chronic post-surgical pain. This step is crucial in translating early identification of a high-risk population into preventive policies. Using a semi-structured interview, the investigators aim to gather this additional information, which is essential in the development of an (individualized) biopsychosocial care pathway in the future.",[338,339,340],"Elective Surgery","Anxiety","Chronic Post Surgical Pain","2026-04-28",{"date":343,"type":34},"2026-04-29",{"date":345,"type":34},"2025-11-15",{"date":347,"type":21},"2026-09-01",{"name":40,"class":41},{"id":350,"slug":351,"hasResults":12,"nctId":352,"briefTitle":353,"officialTitle":354,"acronym":4,"eligibilityCriteria":355,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":356,"targetDuration":4,"studyType":51,"phases":358,"briefSummary":359,"conditions":360,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":362,"startDateStruct":363,"completionDateStruct":365,"leadSponsor":366,"locationsCount":4},"100416636","role-of-exposure-in-hyperacusis-100416636","NCT04705246","Role of Exposure in Hyperacusis","Effect of Psychoeducation Upon Exposure to Sounds and Hyperacusis Severity","Inclusion Criteria:\n\n* primary complaint of hyperacusis\n\nExclusion Criteria:\n\n* primary complaint of misophonia\n* primary complaint of tinnitus\n* undergoing another therapy at the moment of the study",{"count":357,"type":21},5,[53],"This study focuses on patients with a primary complaint of hyperacusis. Hyperacusis has been defined as 'abnormally reduced tolerance to sound'. It shows a high comorbidity with tinnitus, the perception of sound in the absence of a sound source. For the period of one month, hyperacusis and tinnitus severity and exposure to sounds will be evaluated by use of Ecological Momentary Assessment (EMA) in all participants. A novel approach to assessments, EMA prompts participants during their daily life to answer short questionnaires, increasing ecological validity and minimizing the risk for recall and memory biases. At a randomized time point during the one-month period, participants will individually receive a single psychoeducation session (1h) delivered by an experienced audiologist. The goal of the study is to investigate if the psychoeducation session leads to an increase in exposure to sound and a decrease in hyperacusis severity.",[361],"Hyperacusis",{"date":343,"type":34},{"date":364,"type":21},"2027-12-07",{"date":88,"type":21},{"name":40,"class":41},{"id":368,"slug":369,"hasResults":12,"nctId":370,"briefTitle":371,"officialTitle":371,"acronym":372,"eligibilityCriteria":373,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":374,"targetDuration":4,"studyType":51,"phases":376,"briefSummary":377,"conditions":378,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":383,"lastUpdatePostDateStruct":384,"startDateStruct":386,"completionDateStruct":388,"leadSponsor":390,"locationsCount":42},"100586868","stop-sepsis-through-home-monitoring-cooperative-100586868","NCT06920979","Stop Sepsis Through Home Monitoring Cooperative","Stethoscoop","Inclusion Criteria:\n\n* This study will include patients aged 18 years or older, capable of giving informed consent, presenting with signs of severe acute infection with a risk of developing sepsis at the emergency department or at their primary care physician.\n\nExclusion Criteria:\n\n* Patients that are severely ill and require immediate hospitalization Qucik Sepsis Related Organ Failure score (QSOFA) ≥ 1 National Early Warning Score (NEWS) ≥ 5\n* Patients that demonstrate confusion, changes in mental state and\u002For an Mini-Mental State Examination (MMSE) below 26\n* Presence of neuropenic fever\n* Patients currently undergoing immunosuppressive therapy or chemotherapy\n* Patients with human immunodeficiency virus (HIV) or Acquired Immune Deficiency Syndrome (AIDS)\n* Suspicion of appendicitis, suspicion of meningitis or meningeal irritation, suspicion of or high risk of developing endocarditis\n* Complicated operation wounds at the time of screening\n* Proven pneumonia (CURB 65 score ≥ 1)\n* Emphysema, Chronic Obstructive Pulmonary Disease (COPD) GOLD \\>1 or interstitial lung disease\n* Patients with oxygen at home \\> 2 l\u002Fmin on a chronic basis (severe underlying lung disease?)\n* Severe cardiovascular disease including:\n\n  * Severe heart failure New York Heart Association (NYHA) class \\> 1\n  * Endoprosthesis\n  * Cardiac arrhythmia including atrial fibrillation\n  * Severe heart valve abnormalities\n  * Mechanic valve replacement\n  * Recent acute myocardial infarct or coronarography (less than 1y ago)\n  * Severe peripheral vascular morbidity\n* Acute chest pain (suspicion of acute coronary pathology)\n* Suspicion of\u002Fchance of septic arthritis",{"count":375,"type":21},120,[53],"In this study, patients presenting with acute infections at risk of developing sepsis will be followed in their home setting using wearables that provide (semi-)continue monitoring of vital signs as well as through follow up using a designated smartphone application. This is an innovative pilot study that will examine the potential of transmural care through telemonitoring for the first time in patients at risk for developing sepsis. By allowing for active follow-up of vital parameters in a transmural setting, this project aims to reduce the number of hospitalizations as compared to current practice. Furthermore, we aim to the number of patients referred to the emergency department after a visit at their primary care physician. Thereby, we aim to reduce the healthcare burden, yet providing the ability for rapid intervention in case of detarioration of patients, thereby reducing morbidity and mortality as well as associated costs.",[379,380,381,382],"Sepsis","Home Monitoring Follow-up","Infection","Innovativeness","2026-04-27",{"date":385,"type":34},"2026-05-01",{"date":387,"type":34},"2025-02-01",{"date":389,"type":21},"2028-12-31",{"name":40,"class":41},{"id":392,"slug":393,"hasResults":12,"nctId":394,"briefTitle":395,"officialTitle":396,"acronym":397,"eligibilityCriteria":398,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":399,"targetDuration":401,"studyType":22,"phases":4,"briefSummary":402,"conditions":403,"keywords":407,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":383,"lastUpdatePostDateStruct":412,"startDateStruct":413,"completionDateStruct":415,"leadSponsor":417,"locationsCount":42},"100542644","muscle-mass-via-ultrasound-in-cirrhosis-mmuscle-100542644","NCT06345547","Muscle Mass Via UltraSound in Cirrhosis (MMUSCLE)","Prospective Observational Cohort Survey to Assess the Prevalence and Development of Sarcopenia and the Correlation of Muscle Mass and Outcome in Patients With Cirrhosis by Skeletal Muscle Ultrasound.","MMUSCLE","Inclusion Criteria:\n\n* diagnosis of cirrhosis and follow-up in the University Hospital of Antwerp\n\nExclusion Criteria:\n\n* known patient will against participation in the study or against the measures applied in the study\n* a decision made prior to inclusion to stop further treatment of the patient within the next 24 hours\n* no complete remission of malignancy including hepatocellular carcinoma within the past 12 months",{"count":400,"type":21},60,"2 Years","The goal of this observational cohort study is to learn about loss of muscle mass and muscle strength (sarcopenia) in patients with cirrhosis. The main question\\[s\\] it aims to answer are:\n\n* what is the prevalence and development of sarcopenia in cirrhosis?\n* what is the role of malnutrition? Participants will\n\n  * undergo a muscle ultrasound of the lower and upper limb muscles\n  * handgrip strength will be measured\n  * malnutrition screening and assessment\n  * complete a questionnaire to assess quality of life",[404,405,406],"Sarcopenia","Cirrhosis","Malnutrition",[408,409,410,411],"sarcopenia","cirrhosis","malnutrition","skeletal muscle ultrasound",{"date":385,"type":34},{"date":414,"type":34},"2024-05-06",{"date":416,"type":21},"2028-03-31",{"name":40,"class":41},{"id":419,"slug":420,"hasResults":12,"nctId":421,"briefTitle":422,"officialTitle":422,"acronym":423,"eligibilityCriteria":424,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":425,"targetDuration":4,"studyType":51,"phases":426,"briefSummary":427,"conditions":428,"keywords":432,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":383,"lastUpdatePostDateStruct":439,"startDateStruct":440,"completionDateStruct":442,"leadSponsor":444,"locationsCount":42},"100522161","cooley--study-acute-on-chronic-liver-failure-using-the-cytosorb-device-100522161","NCT06079021","COOLEY- Study: aCute On chrOnic Liver failurE Using the cYtosorb Device","COOLEY","Inclusion Criteria:\n\n* adult patients (≥ 18 years) admitted to the University Hospital of Antwerp (UZA), Belgium.\n\n  * Written informed consent from patient or if not possible due to encephalopathy (\\> grade 2): legal representative\n  * acute-on-chronic liver failure (ACLF) grade ≥ 2:\n\n    * Acute decompensation event (identifiable trigger)\n    * Hepatic encephalopathy grade ≥ 2\n    * Acute kidney injury (AKI) according to Kidney Disease: Improving Global Outcome (KDIGO) criteria stage 3 (≥ 3-fold increase of serum creatinine OR increase of serum creatinine to ≥ 4 mg\u002Fdl OR urine output ≤ 0.3 ml\u002Fkg\u002Fh for ≥ 24 hours OR anuria for ≥ 12 hours)\n    * Serum bilirubin ≥ 10 mg\u002Fdl\n    * Hemodynamic instability with vasopressor support (norepinephrine \\> 0.05 mcg\u002Fkg\u002Fmin)\n\nExclusion Criteria:\n\n* • known patient will against participation in the study or against the measures applied in the study\n\n  * a decision made prior to inclusion to stop further treatment of the patient within the next 24 hours\n  * no complete remission of malignancy including hepatocellular carcinoma within the past 12 months\n  * ongoing intermittent or CRRT before study inclusion",{"count":50,"type":21},[53],"A Prospective, Single-Center trial, in Patients With Acute on Chronic Liver Failure. Study of Standard Medical Care Plus CytoSorb® Compared to Standard Medical Care Alone in a historical group.",[429,430,404,431],"Acute-On-Chronic Liver Failure","Anticoagulant Adverse Reaction","Ultrasonography",[433,408,434,435,436,411,437,438],"acute on chronic liver failure","citrate anticoagulation","low molecular weight heparins","hand grip strength","hemoadsorption","CRRT",{"date":385,"type":34},{"date":441,"type":34},"2024-06-08",{"date":443,"type":21},"2027-12-31",{"name":40,"class":41},{"id":446,"slug":447,"hasResults":12,"nctId":448,"briefTitle":449,"officialTitle":449,"acronym":450,"eligibilityCriteria":451,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":452,"targetDuration":4,"studyType":51,"phases":454,"briefSummary":456,"conditions":457,"keywords":459,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":463,"lastUpdatePostDateStruct":464,"startDateStruct":465,"completionDateStruct":467,"leadSponsor":469,"locationsCount":470},"100635853","phase-3-folicolor-trial-following-therapy-response-through-liquid-biopsy-in-metatstatic-colorectal-cancer-patients-100635853","NCT07558083","FOLICOLOR TRIAL: Following Therapy Response Through Liquid Biopsy in Metatstatic Colorectal Cancer Patients","FOLICOLOR","Inclusion Criteria:\n\n* Man or woman ≥ 18 years of age at the time the informed consent is obtained\n* ECOG performance status of 0-2\n* Histologically or cytologically confirmed adenocarcinoma of the colon or rectum in subjects with unresectable metastatic (M1) disease\n* There should be at least 1 uni-dimensionally measurable (min. 10mm) using conventional crosssectional imaging techniques (CT or MRI scan). Lesion must not be chosen from a previously irradiated field, unlessnthere has been documented disease progression in that field after irradiation and prior to randomization. All sites of disease must be evaluated ≤ 28 days prior to randomization\n* Adequate hematology, renal, hepatic and coagulation function (at treating physician's discretion)\n* Adequate blood results for treatment (at treating physician's discretion)\n* Starting a first line treatment\n\nExclusion Criteria:\n\n* History of prior or concurrent central nervous system metastases\n* History of other malignancy, except:\n\nMalignancy treated with curative intent and with no known active disease present for ≥ 3 years prior to randomization and felt to be at low risk for recurrence by the treating physician.\n\nAdequately treated non-melanomatous skin cancer or lentigo maligna without evidence of disease.\n\nAdequately treated cervical carcinoma in situ without evidence of disease. Prostatic intraepithelial neoplasia without evidence of prostate cancer\n\n* Prior chemotherapy or other systemic anticancer therapy for the treatment of metastatic colorectal carcinoma including but not limited to bevacizumab and anti-EGFR therapy (e.g. cetuximab, panitumumab, erlotinib, gefitinib, lapatinib)\n* Prior adjuvant chemotherapy (including oxaliplatin therapy) or other adjuvant systemic anticancer therapy including but not limited to bevacizumab and anti-EGFR therapy (e.g. cetuximab, panitumumab, erlotinib, gefitinib, lapatinib) for the treatment of colorectal cancer ≤ 6 months prior to randomization with the following exceptions: Subjects may have received prior fluoropyrimidine therapy if administered solely for the purpose of radiosensitization for the adjuvant or neoadjuvant treatment of rectal cancer.\n* Radiotherapy ≤ 14 days prior to randomization. Subjects must have recovered from all radiotherapy-related toxicities.",{"count":453,"type":21},150,[455],"PHASE3","The FOLICOLOR trial aims to evaluate whether a liquid biopsy-guided follow-up strategy can improve outcomes in patients with unresectable, metastatic colorectal cancer (mCRC) receiving first-line systemic treatment. The approach uses NPY methylation-based circulating tumor DNA (ctDNA) analysis from blood samples to monitor treatment response and guide clinical decision-making. Eligible patients are adults diagnosed with unresectable, metastatic colorectal cancer who are starting first-line treatment. The primary goal is to demonstrate a clinically meaningful benefit, particularly in terms of quality of life (QoL) and reduction of treatment-related toxicity, by allowing earlier and more personalized therapeutic adjustments based on liquid biopsy findings.",[458],"Advanced Colorectal Cancer",[460,461,462],"NPY Methylation","Liquid Biopsy","advanced colorectal cancer patients","2026-04-22",{"date":317,"type":34},{"date":466,"type":34},"2021-08-16",{"date":468,"type":21},"2031-08",{"name":40,"class":41},9,{"id":472,"slug":473,"hasResults":12,"nctId":474,"briefTitle":475,"officialTitle":476,"acronym":477,"eligibilityCriteria":478,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":479,"targetDuration":4,"studyType":51,"phases":481,"briefSummary":482,"conditions":483,"keywords":489,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":493,"lastUpdatePostDateStruct":494,"startDateStruct":496,"completionDateStruct":498,"leadSponsor":500,"locationsCount":501},"100472805","the-belgian-endothelial-surgical-transplant-of-the-cornea-100472805","NCT05436665","The Belgian Endothelial Surgical Transplant of the Cornea","The Belgian Endothelial Surgical Transplant of the Cornea:Clinical and Patient-reported Outcomes of Descemet Stripping Automated Endothelial Keratoplasty(DSAEK) Versus Descemet Membrane Endothelial Keratoplasty(DMEK)","BESTCornea","Inclusion Criteria:\n\n* Fuchs Endothelial Dystrophy (FED);\n* Bullous Keratopathy (BK);\n* Other miscellaneous causes of endothelial dysfunction including decompensation of a previous corneal graft;\n* Pseudophakic (post cataract surgery);\n* Patients over 18 with the capacity to read and to understand the study information and to give informed consent, as well as study quality of life questionnaires;\n* Patients willing and capable to attend the 3, 6, and 12-month follow-up appointments.\n\nExclusion Criteria:\n\n* Inability to provide informed consent;\n* Patients unable to attend the proposed follow up;\n* Inclusion of the fellow eye in the study;\n* Complex surgery combined with multiple pathologies (i.e., glaucoma surgery);\n* Other contraindications to lamellar corneas surgery;\n* Patients who elect not to participate;\n* Patients under 18 years of age;\n* Patients that are currently pregnant or breastfeeding;\n* Phakic patients with no direct plan to perform cataract surgery.",{"count":480,"type":21},220,[53],"This study is designed as a randomised multicentric parallel group pragmatic trial of Descemet Stripping Automated Endothelial Keratoplasty (DSAEK) versus Descemet Membrane Endothelial Keratoplasty (DMEK) in corneal endothelial decompensation. the purpose is to compare the clinical and patient reported outcomes of both therapies across a broad range of indications.",[484,485,486,487,488],"Corneal Edema","Corneal Endothelial Disorder","Fuchs' Endothelial Dystrophy","Bullous Keratopathy","Pseudophakic Bullous Keratopathy",[490,491,492],"DMEK","DSAEK","UT-DSAEK","2026-03-30",{"date":495,"type":34},"2026-04-03",{"date":497,"type":34},"2022-08-10",{"date":499,"type":21},"2028-06-06",{"name":40,"class":41},11,{"id":503,"slug":504,"hasResults":12,"nctId":505,"briefTitle":506,"officialTitle":507,"acronym":4,"eligibilityCriteria":508,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":509,"enrollmentInfo":510,"targetDuration":512,"studyType":22,"phases":4,"briefSummary":513,"conditions":514,"keywords":516,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":519,"lastUpdatePostDateStruct":520,"startDateStruct":522,"completionDateStruct":524,"leadSponsor":525,"locationsCount":42},"100612580","airway-microbiome-of-patients-with-protracted-bacterial-bronchitis-100612580","NCT07255430","Airway Microbiome of Patients With Protracted Bacterial Bronchitis","Interaction Between Microbiome, Virome and Host Immunity Response in the Context of Protracted Bacterial Bronchitis","Inclusion Criteria:\n\n* Children with PBB diagnosis according to case definition\n* Consent form signed by parents or legal guardians\n\nExclusion Criteria:\n\n* Comorbidities (HIV, asthma, chronic obstructive pulmonary disease, diabetes)\n* Have had serious illnesses (meningitis, pneumonia, bacteremia, empyema, etc) in the previous three months, identified only at the time of enrollment.\n* Have chronic respiratory conditions at the time of enrollment (non-PBB bronchiectasis not caused by PBB, CF, allergy, etc.).\n* Having received mechanical ventilation.\n* Having been hospitalized or used antibiotics in the previous three months at the time of enrollment.","5 Years",{"count":511,"type":21},160,"12 Months","This project aims to assess the relationship between the microbiome and virome composition, the immune responses, and the respiratory health of children with protracted bacterial bronchitis (PBB). In addition, we aim to evaluate how the standard treatment with azithromycin interacts with the components of the microbiome, virome and immune biomarkers.",[515],"Protracted Bacterial Bronchitis",[517,515,518],"cough","microbiome","2026-03-18",{"date":521,"type":34},"2026-03-19",{"date":523,"type":34},"2026-01-07",{"date":323,"type":21},{"name":40,"class":41},{"id":527,"slug":528,"hasResults":12,"nctId":529,"briefTitle":530,"officialTitle":531,"acronym":532,"eligibilityCriteria":533,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":534,"targetDuration":4,"studyType":51,"phases":536,"briefSummary":537,"conditions":538,"keywords":544,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":560,"lastUpdatePostDateStruct":561,"startDateStruct":563,"completionDateStruct":565,"leadSponsor":567,"locationsCount":568},"100627960","a-study-of-barretts-esophagus-patients-optimization-of-a-risk-model-to-better-predict-the-development-of-cancer-recurrence-and-the-effect-of-risk-profile-disclosure-on-patient-quality-of-life-and-fear-of-cancer-100627960","NCT07455422","A Study of Barrett's Esophagus Patients: Optimization of a Risk Model to Better Predict the Development of Cancer Recurrence and the Effect of Risk Profile Disclosure on Patient Quality of Life and Fear of Cancer","A Randomized Controlled Trial Using Endoscopic Brush Cytology and Single Cell Clonal Dynamics of Early ESOPHAGEAL ADENOCARCINOMA for Assessing Effects on Quality of Life, Cancer Worry and Defining Cost-Effective Surveillance Strategies","Endeavor-2","Inclusion Criteria:\n\n* Patients with known BE undergoing endoscopy for possible treatment by EMR or ESD due to suspicion of T1 oesophageal Barrett cancer\n* Capable of receiving informed consent and of giving permission\n* Age 18 and upward\n\nExclusion Criteria:\n\n* Patients with current known malignancy of the gastrointestinal tract other than the esophageal lesion\n* Patients refusing randomization and corresponding follow-up intervals based on biomarker profile\n* Patients with severe co-morbidity that prohibits endoscopic therapy under sedation or conscious sedation (such as severe cardiac or pulmonary disease)\n* Esophageal varices\n* Uncontrollable coagulation disorders\n* Undergoing\u002Fplanned chemotherapy or immunotherapy or received chemotherapy \\\u003C 6 months prior to endoscopy\n* Undergoing\u002Fplanned radiotherapy within the esophageal region or received radiotherapy \\\u003C 6 months prior to endoscopy\n* WHO score \\>3",{"count":535,"type":21},266,[53],"The goal of the study is:\n\n* The collection of various tissue samples (blood, biopsies and \"esophageal brushes\") and their analysis.\n* To test a risk model based on genetic analyses (DNA-FISH and so-called single cell sequencing) on esophageal tissue samples.\n* Evaluating the quality of life of Barrett's Esophagus patients and the degree of fear of getting cancer.\n\nPatients with a Barrett's Esophagus can participate in the study if they are minimally 18 years old, are capable of giving informed consent (fully understanding what the study entails before giving consent to participate), have Barrett Esophagus and are referred to one of the participating centers due to suspicion of early esophageal cancer, for which the participant will be evaluated by endoscopic imaging and biopsy.\n\nStudy procedures:\n\nAn intake consultation will be planned, wherein the eligibility criteria will be assessed, and participant characteristics will be collected.\n\nA routine gastroscopy will be planned twice during which several minimally-invasive interventions will be performed: drawing a blood sample, brush cytology during the endoscopy (a brush is used to obtain cells from the surface of the esophagus) and obtaining biopsy samples (small pieces of tissue). Each participant will need to undergo all the interventions.\n\nPatients will have to complete questionnaires at several time points to assess their quality of life (EQ-5D-DL questionnaire) and fear of cancer recurrence (Cancer Worry Scale).\n\nThis study is a randomized trial, meaning the study participants will be divided into two groups by the computer. One group will be informed of their risk profile, established based on the genetic analyses. The other group will not be informed of their risk profile. All patients will be followed-up in a more intensive surveillance schedule compared to the standard of care, for study purposes.",[539,540,541,542,543],"Barrett Esophagus","Barrett Esophagus Adenocarcinoma","Adenocarcinoma - GEJ","Gastroenterology","Gastroenterological Cancer",[539,545,546,547,548,549,550,551,552,553,554,555,556,557,558,559],"Barrett","DNA FISH","Genetic profiling","Adenocarcinoma","Brush cytology","Cancer worry","Disease free survival","Randomized controlled trial","RCT","Endoscopic mucosal resection","Endoscopic submucosal dissection","EMR","ESD","Quality of life","Health-Economic analysis","2026-03-02",{"date":562,"type":34},"2026-03-06",{"date":564,"type":21},"2026-06-01",{"date":566,"type":21},"2030-12-31",{"name":40,"class":41},10,{"id":570,"slug":571,"hasResults":12,"nctId":572,"briefTitle":573,"officialTitle":574,"acronym":575,"eligibilityCriteria":576,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":577,"targetDuration":4,"studyType":51,"phases":578,"briefSummary":579,"conditions":580,"keywords":583,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":587,"lastUpdatePostDateStruct":588,"startDateStruct":590,"completionDateStruct":592,"leadSponsor":593,"locationsCount":470},"100556305","a-study-of-barretts-esophagus-patients-to-investigate-quality-of-life-and-fear-of-cancer-and-optimize-a-risk-model-based-on-biomarkers-and-new-technologies-to-better-predict-the-development-of-cancer-100556305","NCT06523374","A Study of Barrett's Esophagus Patients to Investigate Quality of Life and Fear of Cancer, and Optimize a Risk Model Based on Biomarkers and New Technologies to Better Predict the Development of Cancer","Endoscopic Brush Cytology and Single Cell Clonal Dynamics of Early Esophageal Adenocarcinoma for Defining Cost Effective Surveillance Strategies and Prediction of Cancer Recurrence: Prospective Pilot Cohort Study in Preparation of a Randomized Controlled Trial to Determine the Feasibility of a Risk Stratification Model for Barrett Esophagus Patients Based on Brush Cytology, and to Test Novel High Throughput Methods for Assessing Biomarkers for Future Use","Endeavor-1","Inclusion Criteria:\n\n* Patients with known BE undergoing endoscopy for possible treatment by EMR or ESD due to suspicion of early esophageal Barrett cancer\n* Capable of receiving informed consent and of giving permission\n* Age 18 and upward\n\nExclusion Criteria:\n\n* Patients with current known malignancy of the gastrointestinal tract other than the esophageal lesion\n* Patients with severe co-morbidity that prohibits endoscopic therapy under sedation or conscious sedation (such as severe cardiac or pulmonary disease)\n* Esophageal varices\n* Uncontrollable coagulation disorders\n* Undergoing chemotherapy or immunotherapy or received chemotherapy \\\u003C 6 weeks prior to endoscopy\n* Undergoing radiotherapy within the esophageal region or received chemotherapy \\\u003C 6 months prior to endoscopy\n* WHO score \\> 3",{"count":20,"type":21},[53],"This study serves, in part, to prepare for a future large cohort study. The goal of the study is:\n\n1. The collection of various tissue samples (blood, biopsies and \"esophageal brushes\") and their analysis.\n2. To set up standardized methods for different genetic analyses (DNA-FISH and so-called single cell sequencing) on the esophageal tissue samples.\n3. Evaluating the quality of life of Barrett's Esophagus patients and the degree of fear of getting cancer.\n\nPatients with a Barrett's Esophagus can participate in the study if they are minimally 18 years old, are capable of giving informed consent (fully understanding what the study entails before giving consent to participate), have Barrett Esophagus and are referred to one of the participating centers due to suspicion of high-grade dysplasia or early esophageal cancer, for which the participant will be evaluated by endoscopic imaging and biopsy.\n\nStudy procedures:\n\n* An intake consultation will be planned, wherein the eligibility criteria will be assessed, and participant characteristics will be collected.\n* A routine gastroscopy will be planned twice during which several minimally-invasive interventions will be performed: drawing a blood sample, brush cytology during the endoscopy (a brush is used to obtain cells from the surface of the esophagus) and obtaining biopsy samples (small pieces of tissue). Each participant will need to undergo all the interventions.\n* Patients will have to complete questionnaires at three time points to assess their quality of life (EQ-5D-DL questionnaire) and fear of cancer recurrence (Cancer Worry Scale).",[581,582],"Barrett's Esophagus","Esophageal Adenocarcinoma",[545,581,584,585,586],"Endeavor","Esophageal cancer","Esophageal adenocarcinoma","2026-02-20",{"date":589,"type":34},"2026-02-24",{"date":591,"type":34},"2025-08-13",{"date":66,"type":21},{"name":40,"class":41},{"id":595,"slug":596,"hasResults":12,"nctId":597,"briefTitle":598,"officialTitle":599,"acronym":600,"eligibilityCriteria":601,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":602,"enrollmentInfo":603,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":605,"conditions":606,"keywords":608,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":611,"lastUpdatePostDateStruct":612,"startDateStruct":614,"completionDateStruct":616,"leadSponsor":618,"locationsCount":42},"100624810","is-high-resolution-endotracheal-tube-leak-data-indicative-of-the-development-of-post-extubation-stridor-in-children-100624810","NCT07414472","Is High Resolution Endotracheal Tube Leak Data Indicative of the Development of Post-extubation Stridor in Children?","PES: Is High Resolution Endotracheal Tube Leak Data Indicative of the Development of Post-extubation Stridor in Children?","PES","Inclusion Criteria:\n\n* Age 0 - 16 years\n* Ventilation via endotracheal tube for at least 6 hours\n\nExclusion Criteria:\n\n* None","16 Years",{"count":604,"type":21},400,"Post extubation stridor (PES) is a common and possibly serious complication of invasive ventilation via endotracheal tube (ETT) in pediatric intensive care (PICU) patients. The source of the PES is either temporary in the case of post-intubation laryngeal edema, or long-term in the case of subglottic stenosis.",[607],"Post Extubation Stridor",[609,610],"Pediatric","Post extubation stridor","2026-02-09",{"date":613,"type":34},"2026-02-17",{"date":615,"type":34},"2025-06-30",{"date":617,"type":21},"2026-06-30",{"name":40,"class":41},{"id":620,"slug":621,"hasResults":12,"nctId":622,"briefTitle":623,"officialTitle":624,"acronym":625,"eligibilityCriteria":626,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":627,"targetDuration":4,"studyType":51,"phases":629,"briefSummary":631,"conditions":632,"keywords":638,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":654,"lastUpdatePostDateStruct":655,"startDateStruct":657,"completionDateStruct":659,"leadSponsor":661,"locationsCount":662},"100607479","phase-4-creep-and-maintenance-fluid-sodium-chloride-administration-reduction-in-critically-ill-adults-100607479","NCT07189091","CReep and Maintenance flUid Sodium Chloride ADministration rEduction in cRitically Ill adultS","Effect of Reduced Sodium Chloride in Fluid Creep and Maintenance Fluids in Critically Ill Adults: A Randomized Controlled Trial","CRUSADERS","Inclusion criteria\n\n1. At least 18 years of age\n2. Patients who are admitted to the ICU for medical or surgical emergencies, including complications of elective surgery\n3. The treating physician expects the patient will still require ICU care in two days, indicating a severe or complex condition at enrollment\n4. The patient is expected to receive at least 300 mL of fluid creep or at least 1 liter of maintenance fluid according to study-arm during the first 24h after inclusion\n\nExclusion Criteria:\n\n1. A contraindication to hypotonic fluids due to risk of brain edema (including traumatic brain injury, major stroke, intracranial\u002Fsubarachnoid hemorrhage, meningoencephalitis, intracranial malignancies…), with the timing and clinical judgment left at the discretion of the treating physician.\n2. Hyponatremia below 131 mmol\u002FL at admission\n3. Admission solely for treatment of fluid accumulation due to cardiac decompensation, without other acute medical conditions requiring ICU-level care. Note: Patients with heart failure as a comorbidity, those on chronic diuretic therapy, or presenting with edema\u002Fbilateral lung infiltrates due to other conditions (e.g., sepsis, pneumonia) are not excluded.\n4. Patient's death is deemed imminent and inevitable, admission for palliative care or admission solely for organ donation\n5. Patient receiving chronic renal replacement therapy\n6. Patients referred after a stay of more than 24 hours in another ICU\n7. Patients randomized in CRUSADERS before\n8. Patient is co-enrolled in an unapproved concomitant ICU-trial or in any trial with an intervention that affects fluid administration or fluid balance\n\nAdditional exclusion criteria for the SALADIN nested substudy\n\n1. Patients expected to require renal replacement therapy within 24 hours\n2. Increased insensible fluid losses: burns, extensive wounds or skin defects or massive diarrhea,…\n3. Patients without a urine catheter\n4. Patients expected to require bladder irrigation within 24 hours\n5. Patients on chronic treatment with loop or thiazide diuretics (including combination preparations)",{"count":628,"type":21},640,[630],"PHASE4","This study is enrolling adult patients who require a prolonged stay in the intensive care unit (ICU). These patients often receive large amounts of intravenous fluids, which can contain more salt (sodium and chloride) than the body normally needs. Extra salt and water can build up in the body and may delay recovery.\n\nThe study will test two strategies:\n\nFluid creep: These are fluids used to dilute medications or keep intravenous lines open. Usually, the choice is based on habit. In the intervention group, a salt-free glucose 5% solution will be used (if the responsible pharmacist confirms it is compatible with the medication).\n\nMaintenance fluids: These fluids cover daily needs for water and electrolytes. In the intervention group, a lower-salt solution (NaCl 0.3% in glucose 3.3%) will be given, with volume decided by the treating physician.\n\nThe comparison group will receive usual care: NaCl 0.9% (commonly called \"normal saline\") for fluid creep, and an isotonic solution (PlasmaLyte) for maintenance fluids.\n\nThe main outcome is the number of days patients are alive and free of life support (such as ventilator or dialysis) during the first 90 days. Other outcomes include abnormal sodium, chloride, or glucose levels, fluid balance and need for diuretics, kidney injury, use of dialysis, time on the ventilator, survival, and length of ICU and hospital stay.\n\nA smaller substudy (SALADIN) will measure in detail how the body handles sodium, chloride, and water using additional calculation on blood tests, urine collections, body weight, and bioimpedance analysis",[633,634,635,636,637],"Critical Care, Intensive Care","Fluid Accumulation","Fluid and Electrolyte Imbalance","Critical Illness","Fluid Balance Outcomes",[639,640,636,641,642,643,644,645,646,647,648,649,650,27,651,652,653],"Intensive Care Unit","Critically Ill","Intravenous fluids","Maintenance fluids","Fluid Creep","Sodium chloride reduction","Salt reduction","Hypotonic fluids","Saline (NaCl 0.9%)","Fluid balance","Electrolyte disorders","Glycemic control","Mechanical ventilation","Organ support","Hyponatremia","2026-01-30",{"date":656,"type":34},"2026-02-03",{"date":658,"type":34},"2025-10-07",{"date":660,"type":21},"2028-07-30",{"name":40,"class":41},4,{"id":664,"slug":665,"hasResults":12,"nctId":666,"briefTitle":667,"officialTitle":667,"acronym":668,"eligibilityCriteria":669,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":670,"targetDuration":4,"studyType":51,"phases":672,"briefSummary":673,"conditions":674,"keywords":675,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":680,"lastUpdatePostDateStruct":681,"startDateStruct":683,"completionDateStruct":685,"leadSponsor":686,"locationsCount":42},"100618870","assessment-of-the-effect-of-hypoglossal-nerve-stimulation-therapy-on-upper-airway-collapsibility-during-drug-induced-sleep-endoscopy-100618870","NCT07337239","Assessment of the Effect of Hypoglossal Nerve Stimulation Therapy on Upper Airway Collapsibility During Drug-induced Sleep Endoscopy","HNS-CoDSE","Inclusion Criteria:\n\n* 18 years or older.\n* Treated with HNS-therapy for OSA (AHI ≥15\u002Fhour sleep)\n* Capable of giving informed consent\n* Baseline polysomnography performed at Antwerp University Hospital\n\nExclusion Criteria:\n\n* Patients did not receive HNS-therapy at the Antwerp University Hospital\n* Central apneas accounting for ≥25% of total apneas during baseline polysomnography\n* Known medical history of intellectual disability, memory disorders or current psychiatric disorders (psychotic illness, major depression, or acute anxiety attacks as mentioned by the participant).\n* Simultaneous use of other treatment modalities to treat OSA (outside of HNS-therapy)\n* Esophageal ulceration, tumors, diverticulitis, bleeding varices, sinusitis, epistaxis, recent nasopharyngeal surgery\n* Pregnancy or willing to become pregnant\n* Excessive alcohol or drug use (\\> 20 alcohol units\u002Fweek or any use of hard drugs)",{"count":671,"type":21},21,[53],"This clinical trial will evaluate the effect of treatment with hypoglossal nerve stimulation on the underlying mechanisms of obstructive sleep apnea. Several disease mechanism parameters are known to be associated with obstructive sleep apnea. However, currently, only the location of upper airway collapse is routinely examined in clinical practice using sleep endoscopy. Among other parameters, airway collapsibility is a widely studied mechanism. This parameter indicates how easily a patient's upper airway tends to collapse and can be assessed with additional measurements during sleep endoscopy.\n\nThe aim of this trial is to investigate the effect of hypoglossal nerve stimulation on collapsibility during sleep endoscopy. This information will provide a better understanding of the physiological mechanisms of hypoglossal nerve stimulation. In the long term, the investigators hope this knowledge will allow for more personalized care by tailoring treatment to the specific needs of each patient.",[80],[676,677,678,679],"OSA","DISE","Endotyping","Collapsibility","2026-01-06",{"date":682,"type":34},"2026-01-13",{"date":684,"type":21},"2026-01",{"date":443,"type":21},{"name":40,"class":41},""]